Continuous manufacturing market is projected to grow at an annualized rate of over 15%, till 2030 By Roots Analysis

Roots Analysis has done a detailed study on Continuous Manufacturing Market (Small Molecules and Biologics), 2020 – 2030, covering key aspects of the industry and identifying future growth opportunities.

To order this 310+ page report, which features 110+ figures and 200+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/continuous-manufacturing/308.html

Key Market Insights

§  Eminent representatives from prominent contract service provider companies / organizations are both optimistic and cautious regarding the rising interest in continuous flow technologies, and its adoption

§  Over 60 companies across the globe claim to manufacture drug products / drug substances using the continuous manufacturing technique, either for in-house requirements or for contract service engagements

§  The market landscape features the presence of several well-established players, most of which claim to manufacture small molecules via the continuous technique, and are based in the developed geographies

§  Companies have established continuous drug manufacturing facilities for diverse types of dosage forms in various geographies; Europe and North America have emerged as the key hubs for these facilities

§  Several patents have been filed / granted specifically related to continuous manufacturing of pharmaceutical substances, both industry and non-industry players are actively involved in such efforts

§  Organizations have also extended financial support to aid the research efforts being put by various stakeholders in this domain; the current focus is on investigation of continuous manufacturing technologies

§  Over time, there has been a lot of activity in this arena, including the establishment of several partnerships and investments in capability and capacity expansions and new facilities worldwide

§  Most of the continuous manufacturing capacity belongs to established companies (in-house manufacturers and CMOs), accounting for over 70% of the available capacity across various geographies

§  Involvement of various other stakeholders including continuous equipment providers and modular facility providers is likely to revolutionize the overall manufacturing domain

§  As the adoption of continuous manufacturing technologies increases, the market is likely to witness significant growth; in the short term, majority of service-based revenues is likely to come from drug product related projects

For more information, please visit https://www.rootsanalysis.com/reports/view_document/continuous-manufacturing/308.html

Table of Contents

TABLE OF CONTENTS

1.         PREFACE        

1.1.       Scope of the Report

1.2.       Research Methodology

1.3.       Chapter Outlines

2.         EXECUTIVE SUMMARY

3.         INTRODUCTION

3.1.       Chapter Overview

3.2.       Historical Evolution of Continuous Manufacturing

3.3.       Continuous Manufacturing in the Pharmaceutical Industry

3.3.1.    Regulatory Landscape  

3.3.2.    Early Adopters of Continuous Manufacturing

3.3.3.    Anticipated Shift to Continuous Manufacturing

3.3.4.    Advantages of Continuous Manufacturing

3.3.5.    Key Challenges Associated with Continuous Manufacturing

3.3.6.    Future Perspectives

4.         MARKET LANDSCAPE

4.1.       Chapter Overview

4.2.       Companies with Expertise in Continuous Manufacturing: Overall Market Landscape

4.2.1.    Analysis by Year of Establishment

4.2.2.    Analysis by Company Size

4.2.3.    Analysis by Purpose of Manufacturing

4.2.4.    Analysis by Scale of Operation

4.2.5.    Analysis by Location of Headquarters

4.2.6.    Analysis by Location of Continuous Manufacturing Facilities

4.2.7.    Analysis by Type of Drug Molecule

4.2.8.    Analysis by Type of Continuous Manufacturing Related Service

4.2.9.    Analysis by Type of Dosage Form

4.2.10.  Heat Map: Analysis by Company Size and Location of Headquarters

4.2.11.  Information on Production Capacity

4.2.12.  Logo Landscape: Analysis by Year of Establishment and Company Size 

4.2.13.  Grid Representation: Analysis by Scale of Operation, Type of Continuous Manufacturing Related Service and Type of Dosage Form

4.2.14.  Geographical Map: Analysis by Location of Continuous Manufacturing Facilities and Type of Drug Molecule

5.         COMPANIES WITH EXPERTISE IN CONTINUOUS MANUFACTURING IN NORTH AMERICA: PROFILES

5.1.       Chapter Overview

5.2.       AbbVie Contract Manufacturing

5.2.1.    Company Overview

5.2.2.    Service Portfolio

5.2.3.    Continuous Manufacturing Capabilities and Facilities

5.2.4.    Recent Developments and Future Outlook

5.3.       Cambrex

5.3.1.    Company Overview

5.3.2.    Service Portfolio

5.3.3.    Continuous Manufacturing Capabilities and Facilities

5.3.4.    Recent Developments and Future Outlook

5.4.       Patheon

5.4.1.    Company Overview

5.4.2.    Service Portfolio

5.4.3.    Continuous Manufacturing Capabilities and Facilities

5.4.4.    Recent Developments and Future Outlook

5.5.       SK biotek

5.5.1.    Company Overview

5.5.2.    Service Portfolio

5.5.3.    Continuous Manufacturing Capabilities and Facilities

5.5.4.    Recent Developments and Future Outlook

6.         COMPANIES WITH EXPERTISE IN CONTINUOUS MANUFACTURING IN EUROPE: PROFILES

6.1.       Chapter Overview

6.2.       Ajinomoto Bio-Pharma Services

6.2.1.    Company Overview

6.2.2.    Service Portfolio

6.2.3.    Continuous Manufacturing Capabilities and Facilities

6.2.4.    Recent Developments and Future Outlook

6.3.       Almac

6.3.1.    Company Overview

6.3.2.    Service Portfolio

6.3.3.    Continuous Manufacturing Capabilities and Facilities

6.3.4.    Recent Developments and Future Outlook

6.4.       Boehringer Ingelheim BioXcellence™

6.4.1.    Company Overview

6.4.2.    Service Portfolio

6.4.3.    Continuous Manufacturing Capabilities and Facilities

6.4.4.    Recent Developments and Future Outlook

6.5.       CordonPharma

6.5.1.    Company Overview

6.5.2.    Service Portfolio

6.5.3.    Continuous Manufacturing Capabilities and Facilities

6.5.4.    Recent Developments and Future Outlook

6.6.       Hovione

6.6.1.    Company Overview

6.6.2.    Service Portfolio

6.6.3.    Continuous Manufacturing Capabilities and Facilities

6.6.4.    Recent Developments and Future Outlook

6.7.       Lonza

6.7.1.    Company Overview

6.7.2.    Service Portfolio

6.7.3.    Continuous Manufacturing Capabilities and Facilities

6.7.4.    Recent Developments and Future Outlook

7.         COMPANIES WITH EXPERTISE IN CONTINUOUS MANUFACTURING IN ASIA-PACIFIC: PROFILES

7.1.       Chapter Overview

7.2.       Kaneka

7.2.1.    Company Overview

7.2.2.    Service Portfolio

7.2.3.    Continuous Manufacturing Capabilities and Facilities

7.2.4.    Recent Developments and Future Outlook         

7.3.       WuXi AppTec

7.3.1.    Company Overview

7.3.2.    Service Portfolio

7.3.3.    Continuous Manufacturing Capabilities and Facilities

7.3.4.    Recent Developments and Future Outlook                     

8.         RECENT PARTNERSHIPS AND COLLABORATIONS

8.1.       Chapter Overview

8.2.       Partnership Models

8.3.       List of Partnerships and Collaborations

8.3.1.    Analysis by Year of Partnership

8.3.2.    Analysis by Type of Partnership

8.3.3.    Analysis by Scale of Operation

8.3.4.    Analysis by Type of Drug Molecule

8.3.5.    Analysis by Type of Continuous Manufacturing Related Service

8.3.6.    Analysis by Type of Dosage Form

8.3.7.    Most Active Players: Analysis by Number of Partnerships

8.3.8.    Regional Analysis

8.3.8.1. Intercontinental and Intracontinental Agreements

9.         RECENT EXPANSIONS

9.1.       Chapter Overview

9.2.       Recent Expansions

9.2.1.    Analysis by Year of Expansion

9.2.2.    Analysis by Type of Expansion

9.2.3.    Analysis by Expanded Scale of Expansion

9.2.4.    Analysis by Type of Drug Molecule

9.2.5.    Analysis by Type of Continuous Manufacturing Related Service

9.2.6.    Analysis by Type of Dosage Form

9.2.7.    Most Active Players: Analysis by Number of Expansions

9.2.8.    Regional Analysis

9.2.8.1. Analysis by Location of Expansion Project

10.        CAPACITY ANALYSIS

10.1.     Chapter Overview

10.2.     Assumptions and Methodology

10.3.     Global, Continuous Manufacturing Capacity for Small Molecule APIs

10.3.1.  Analysis by Company Size

10.3.2. Analysis by Purpose of Manufacturing

10.3.3.  Analysis by Scale of Operation

10.3.4.  Analysis by Location of Headquarters

10.3.4.  Analysis by Location of Continuous Manufacturing Facilities

10.4.     Global, Continuous Manufacturing Capacity for Small Molecule End Products

10.4.1.  Analysis by Company Size

10.4.2. Analysis by Purpose of Manufacturing

10.4.3.  Analysis by Scale of Operation

10.4.4.  Analysis by Location of Headquarters

10.4.5.  Analysis by Location of Continuous Manufacturing Facilities

10.5.     Global, Continuous Manufacturing Capacity for Biologic

10.5.1.  Analysis by Company Size

10.5.2. Analysis by Purpose of Manufacturing

10.5.3.  Analysis by Scale of Operation

10.5.4.  Analysis by Location of Headquarters

10.5.5.  Analysis by Location of Continuous Manufacturing Facilities

11.        ACADEMIC GRANT ANALYSIS

11.1.     Chapter Overview

11.2.     Scope and Methodology

11.3.     Continuous Manufacturing: List of Academic Grants

11.3.1.  Analysis by Number of Grants

11.3.2.  Analysis by Activity Code

11.3.3.  Analysis by Grant Amount

11.3.4.  Analysis by Focus Area

11.3.5.  Analysis by Support Period

11.3.6   Popular Recipient Organizations: Analysis by Number of Grants

11.3.7   Analysis by Type of Recipient Organization

11.3.8.  Analysis by Funding Institute Centre

11.3.9.  Analysis by Funding Mechanism

11.3.10. Prominent Program Officers: Analysis by Number of Grants

12.        PATENT ANALYSIS

12.1.     Chapter Overview

12.2.     Scope and Methodology

12.3.     Continuous Manufacturing: Patent Analysis

12.3.1.  Analysis by Publication Year

12.3.2.  Analysis by Geography

12.3.3.  Analysis by CPC Symbols

12.3.4.  Emerging Focus Areas

12.3.5.  Analysis by Type of Applicant

12.3.6.  Leading Players: Analysis by Number of Patents

12.3.7.  Continuous Manufacturing: Three-Dimensional Bubble Analysis

12.3.8.  Continuous Manufacturing: Patent Valuation Analysis

12.3.8.1. Leading Patents: Information by Number of Citations

13.        INITIATIVES OF COMPANIES WITH IN-HOUSE CONTINUOUS MANUFACTURING CAPABILITIES

13.1.     Chapter Overview

13.2.     Continuous Manufacturing Initiatives of Leading Companies

13.2.1.  AbbVie

13.2.1.1. Partnered Initiatives

13.2.1.2 In-House Initiatives

13.2.2.  Amgen

13.2.2.1. Partnered Initiatives

13.2.2.2. In-House Initiatives

13.2.3.  Bristol-Myers Squibb

13.2.3.1. Partnered Initiatives

13.2.3.2. In-House Initiatives

13.2.4.  GlaxoSmithKline

13.2.4.1. Partnered Initiatives

13.2.4.2. In-House Initiatives

13.2.5.  Merck

13.2.5.1. Partnered Initiatives

13.2.5.2. In-House Initiatives

13.2.6.  Novartis

13.2.6.1. Partnered Initiatives

13.2.6.2. In-House Initiatives

13.2.7.  Pfizer

13.2.7.1. Partnered Initiatives

13.2.7.2. In-House Initiatives

13.2.8.  Roche

13.2.8.1. Partnered Initiatives

13.2.8.2. In-House Initiatives

13.2.9.  Sanofi

13.2.9.1. Partnered Initiatives

13.2.9.2. In-House Initiatives

14.        CASE STUDY: MODULAR FACILITIES IN PHARMACEUTICAL / BIOTECHNOLOGY INDUSTRY

14.1.     Chapter Overview

14.2.     Historical Background

14.3.     Concept of Modularization

14.3.1.  Types of Modules

14.3.2.  Modular Construction Process

14.4.     Modular Construction in the Pharmaceutical Industry

14.4.1.  Advantages of Modular Construction in the Pharmaceutical Industry

14.5.     Modular Facility Manufacturers

14.5.1.  Distribution by Industry Served

14.5.2.  Distribution by Geography

14.5.3.  Modular Projects Executed / Undertaken

14.6.     Modular Pharmaceutical Cleanrooms

14.6.1.  Cleanroom Classification and Current Standards

14.6.2.  Advantages of Modular Cleanrooms

14.6.3.  Regulations and Standards Concerning Modular Cleanroom Construction

14.7.     Modular Cleanroom Providers

14.7.1.  Distribution by Industry Served

14.7.2.  Distribution by Geography

14.7.3.  Type of Modular Cleanrooms Offered

15.        CASE STUDY: TECHNOLOGY AND EQUIPMENT PROVIDERS

15.1.     Chapter Overview

15.2.     Types of Continuous Manufacturing Technologies

15.3.     Equipment and Technologies for Continuous Manufacturing Small Molecules and Biologics

15.3.1.  Continuous Blending and Mixing Equipment

15.3.2.  Continuous Granulating Equipment

15.3.3.  Continuous Drying Equipment

15.3.4.  Continuous Compression Equipment

15.3.5.  Continuous Coating Equipment

15.3.6.  Continuous Filtration, Continuous Distillation and Continuous Centrifugation Equipment

15.3.7.  Continuous Chromatography Equipment

15.3.8.  Continuous Reactors / Bioreactors

15.3.9.  Full Line Continuous Platforms

15.3.10. Process Analytical Technologies

15.3.11. Other Technologies

15.4.     Logo Landscape: Analysis of Technology Providers by Number and Type of Equipment

16.        CASE STUDY: ROADMAP FOR THE ADOPTION OF CONTINUOUS MANUFACTURING PROCESSES

16.1.     Chapter Overview

16.2.     Key Strategies for the Adoption of Continuous Manufacturing Processes

16.2. 1. Phase I: Process Development and Implementation

16.2. 2. Phase II: Equipment / Technology Development and Installation

16.2. 3. Phase III: Facility / Plant Development and Establishment

16.2. 4. Phase IV: Product Development and Manufacturing

17.        MARKET FORECAST AND OPPORTUNITY ANALYSIS

17.1.     Chapter Overview

17.2.     Forecast Methodology and Key Assumptions

17.3.     Overall, Continuous Manufacturing Market, 2020-2030

17.3.1.  Continuous Manufacturing Market: Distribution by Purpose of Manufacturing, 2020-2030

17.3.2.  Continuous Manufacturing Market: Distribution by Scale of Operation, 2020-2030

17.3.3.  Continuous Manufacturing Market: Distribution by Type of Drug Molecule, 2020-2030

17.3.4.  Continuous Manufacturing Market: Distribution by Type of Continuous Manufacturing Related Service, 2020-2030

17.3.5.  Continuous Manufacturing Market: Distribution by Type of Dosage Form, 2020-2030

17.3.6.  Continuous Manufacturing Market: Distribution by Key Geographical Regions, 2020-2030

17.4.     Continuous Manufacturing Market for Small Molecule, 2020-2030

17.4.1.  Distribution by Purpose of Manufacturing, 2020-2030

17.4.2.  Distribution by Scale of Operation, 2020-2030

17.4.3.  Distribution by Type of Continuous Manufacturing Related Service, 2020-2030

17.4.4.  Distribution by Key Geographical Regions, 2020-2030

17.5.     Continuous Manufacturing Market for Biologic, 2020-2030

17.5.1.  Distribution by Purpose of Manufacturing, 2020-2030

17.5.2.  Distribution by Scale of Operation, 2020-2030

17.5.3.  Distribution by Type of Continuous Manufacturing Related Service, 2020-2030

17.5.4.  Distribution by Key Geographical Regions, 2020-2030

18.        CONCLUSION

18.1.     Chapter Overview

18.2.     Key Takeaways

19.        EXECUTIVE INSIGHTS

19.1.     Chapter Overview

19.2.     Zaiput Flow Technologies

19.2.1.  Company Snapshot

19.2.2.  Interview Transcript: Andrea Adamo, Founder and Chief Executive Officer

19.3.     CONTINUUS Pharmaceuticals

19.3.1.  Company Snapshot

19.3.2.  Interview Transcript: Bayan Takizawa, Co-Founder and Chief Business Officer

19.4.     Snapdragon Chemistry

19.4.1.  Company Snapshot

19.4.2.  Interview Transcript: Eric Fang, Chief Scientific Officer

19.5.     Enzene Biosciences

19.5.1.  Company Snapshot

19.5.2.  Interview Transcript: Himanshu Gadgil, Director and Chief Scientific Officer

19.6.     Pfizer

19.6.1.  Company Snapshot

19.6.2.  Interview Transcript: Nick Thomson, Senior Director Chemical Research and Development

19.7.     University of Strathclyde

19.7.1.  Company Snapshot

19.7.2.  Interview Transcript: Ian Houson, Technical Project Manager

20.        APPENDIX 1: TABULATED DATA

21.        APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com